Slide Deck

1. Executive Summary: The Erosion of Quality in a “Specialty” Wrapper

Stepan Company (SCL), a stalwart of the chemical industry known for its dividend consistency, presents a complex investment case that demands a rigorous, skeptical deconstruction. While the company markets itself as a producer of “specialty” chemicals, a forensic analysis of its financial returns, competitive positioning, and capital allocation reveals a business that is increasingly fighting commoditization forces with capital-intensive strategies that have yet to yield commensurate returns to shareholders.

For decades, Stepan relied on a narrative of stability—buttressed by 58 consecutive years of dividend increases—and its position as a leading merchant producer of surfactants and polyester polyols. However, the last five years have revealed significant cracks in this foundation. Return on Invested Capital (ROIC), the truest measure of a company’s competitive advantage or “moat,” has structurally declined from high-teens/low-twenties percentages to low-single digits (approximately 3.2% TTM as of late 2025). This figure falls well below the company’s estimated Weighted Average Cost of Capital (WACC) of 8.0-9.0%, indicating that, currently, Stepan is destroying shareholder value with every dollar of capital it reinvests into its operations.

The core investment thesis hinges on a pivotal, binary question: Is the recent collapse in profitability a cyclical trough exacerbated by temporary headwinds (raw material inflation, supply chain destocking, one-time start-up costs), or is it a secular erosion of the company’s competitive advantage?

Our extensive analysis suggests that while cyclical factors are undeniably present, structural challenges are significant and perhaps permanent. The company’s heavy reliance on the Surfactants segment (approximately 70% of revenue) exposes it to intense competition from global giants like BASF and, more dangerously, internal production capabilities by its own mega-cap customers (e.g., Procter & Gamble, Unilever). The company’s strategic pivot—investing over $245 million in a new alkoxylation facility in Pasadena, Texas—is a high-stakes bet to move up the value chain into more specialized agricultural and oilfield applications. While technically sound in theory, this capital cycle has severely depressed free cash flow, increased leverage to uncomfortable levels, and has yet to deliver the promised margin expansion.

Despite “adjusted” earnings growth narratives frequently touted by management, GAAP reality shows thin net margins (sub-2%) and a business model acutely sensitive to volatile oleochemical feedstocks (coconut/palm oil). Investors paying ~30x trailing earnings are essentially pricing in a flawless execution of the Pasadena ramp-up and a return to historical margins—a scenario that is far from guaranteed given the competitive intensity of the sector.

2. Industry Dynamics & Competitive Position

To evaluate Stepan effectively, one must first deconstruct the economics of the “specialty” chemicals sectors it inhabits: Surfactants and Polymers. The nomenclature often masks the reality that much of this volume behaves like a commodity, subject to brutal price competition and minimal differentiation.

2.1 The Surfactants Market: Commodity Economics with Specialty Branding

The global surfactants market, valued at approximately $45-48 billion in 2024-2025, is projected to grow at a CAGR of roughly 5.3% through 2034.¹ It is a market characterized by high fragmentation at the bottom but dominated at the top by massive integrated players including BASF SE, Indorama Ventures, Nouryon, Evonik, and Croda International.

Industry Economics and Structural Flaws:

• Barriers to Entry: Moderate to Low. Basic sulfonation technology—the core of Stepan’s business—is mature and widely understood. The primary barriers are not intellectual property or proprietary chemistry, but rather scale, logistical networks, and the capital intensity required to build safe, compliant manufacturing facilities. This allows regional players to chip away at market share, limiting pricing power for incumbents.
• Supplier Power: High. Manufacturers like Stepan are price-takers on key feedstocks like coconut oil, palm kernel oil (PKO), and ethylene oxide. Volatility here directly impacts gross margins, as seen in the 70% spike in coconut oil prices in 2025.³ Stepan attempts to pass these costs through, but the inherent lag in contracts creates quarters of severe margin compression. Unlike fully integrated peers (e.g., Dow, BASF), Stepan does not own the hydrocarbon value chain, leaving it exposed to the spread between feedstock costs and finished goods prices.
• Buyer Power: Extremely High. The end market is concentrated among consumer packaged goods (CPG) giants such as Procter & Gamble, Unilever, and Colgate-Palmolive. These customers possess significant “make vs. buy” leverage. They often maintain massive internal surfactant capacity and utilize merchant producers like Stepan only for “overflow” volume or for niche, smaller-volume formulations that are uneconomical to produce in-house. This structural reality creates a ceiling on Stepan’s pricing power; if they push price too high, the customer simply insources the volume or shifts volume to a competitor like Indorama or Pilot Chemical.⁴

Stepan’s Strategic Positioning:

Stepan positions itself as the “largest merchant producer” of surfactants in the Americas. However, “merchant producer” implies it sells to those who do not produce for themselves or choose not to. This inherently limits its addressable market to smaller “Tier 2 and Tier 3” customers or the marginal requirements of the Tier 1 giants.

• Tier 2/Tier 3 Strategy: Management has explicitly pivoted toward acquiring smaller customers to diversify away from the pricing pressure of the CPG behemoths. In Q2 and Q3 2025, they highlighted adding 400+ new customers.⁵ While this diversifies revenue and reduces single-customer risk, it introduces new inefficiencies. Serving hundreds of smaller accounts increases SG&A (sales force, customer service), logistical complexity (smaller batch sizes, less than truckload shipments), and credit risk. This strategy dilutes operating margins even if it bolsters gross margin percentages slightly.
• Competitive Disadvantage: Stepan lacks the backward integration into petrochemical feedstocks (ethylene) that competitors like Shell or Dow possess. In an inflationary environment for hydrocarbons, integrated players can capture margin at the feedstock level, while Stepan gets squeezed.

2.2 The Polymers Segment: A Cyclical Trap or Secular Winner?

Stepan’s Polymers segment (primarily polyester polyols for rigid foam insulation and phthalic anhydride) accounts for roughly 25-30% of sales but has historically offered higher margins than surfactants.

• Secular Drivers: This business is tethered to the construction cycle and energy efficiency regulations. Polyisocyanurate (PIR) board stock usage in commercial roofing is the key volume driver. As global building codes demand higher R-values (thermal resistance), the demand for rigid polyols increases. This is a legitimate secular tailwind.
• Competitive Landscape: Stepan is a market leader in polyester polyols, competing with Invista (whose aromatic polyester polyol business Stepan acquired in 2021) and Huntsman. The consolidation of Invista has theoretically improved Stepan’s market share and pricing power in this niche.⁶
• Differentiation: There is genuine technical differentiation here. Stepan’s proprietary processes for utilizing recycled polyethylene terephthalate (rPET) in polyols align with sustainability trends. However, 2024-2025 performance has been marred by demand weakness in Europe and China, revealing the segment’s acute cyclicality. The “green” premium has not been sufficient to offset the macroeconomic drag of high interest rates crushing commercial construction activity.

2.3 Evidence of “Moat” (or Lack Thereof)

A true competitive advantage (moat) must manifest in pricing power and superior financial returns over a full economic cycle.

• Pricing Power: Stepan demonstrated an ability to raise prices by ~11-12% in 2025 to offset raw material inflation.⁷ This suggests some pass-through capability. However, this is largely a mechanism to protect absolute gross profit dollars, not margins. Gross margins have compressed from ~15-16% historically to ~11.9% recently ⁸, indicating that while they can pass on costs, they cannot price for value to maintain margin percentage. If they had true pricing power, margins would remain stable or expand during inflation.
• Switching Costs: Low to Medium. In commodity cleaning applications (surfactants), products are largely interchangeable based on chemical specifications. In agricultural and oilfield applications (the focus of the Pasadena plant), switching costs are higher due to regulatory registration (EPA) and formulation specificity. Stepan’s capital pivot to these markets is a rational attempt to build a deeper moat, but it is yet unproven.
• Cost Advantage: Management claims a cost advantage via their continuous sulfonation process, which they state is more efficient than batch processing.⁹ While continuous processing is indeed more efficient for large volumes, this advantage is negated if the company is forced to run smaller batches for its “Tier 2/3” customer strategy. Furthermore, competitors like BASF also utilize continuous sulfonation at even larger scales, neutralizing this advantage.

Conclusion on Industry: Stepan operates primarily in a “commoditized specialty” space. It is not a high-moat compounder like Croda (which focuses on high-value life sciences). It is a processor that earns a spread on raw materials, heavily dependent on volume to cover high fixed costs.

3. Financial Performance: The Erosion of Returns

The quantitative evidence for Stepan’s competitive advantage has deteriorated significantly over the last three to five years. The divergence between “Adjusted EBITDA” narratives provided by management and statutory returns on capital is stark and concerning.

3.1 Return on Invested Capital (ROIC) – The Red Flag

Historically (2012-2021), Stepan generated ROIC in the range of 10% to 13%.¹⁰ This profile characterized a quality industrial business earning a spread above its cost of capital.

• The Decline: In the trailing twelve months (TTM) ending Q3 2025, ROIC has collapsed to approximately 3.18% – 3.2%.¹¹ Even utilizing generous adjustments, returns are well below the estimated WACC of 8.89%.
• Value Destruction: A company earning 3% ROIC while paying ~9% for capital is destroying shareholder value. The “spread” is negative. This indicates that recent growth investments (Pasadena, acquisitions) have not only failed to add value but are actively diluting the quality of the legacy business.
• Drivers of Destruction:

1. Bloated Capital Base: Invested capital has surged due to the Pasadena project ($265M+) and the Invista acquisition, without a corresponding lift in NOPAT (Net Operating Profit After Tax).
2. Margin Compression: NOPAT margins have been halved due to the lag in price recovery and manufacturing inefficiencies during start-ups.

Peer Comparison:

Comparing Stepan’s returns to its peers highlights the underperformance:

• Stepan (SCL): ~3.2% ROIC.¹¹
• Croda International: Historically 10-12%+, currently impacted by cycle but structurally superior due to Life Sciences exposure.¹³
• Innospec (IOSP): Consistently maintains higher margins and ROIC profiles due to niche fuel additive focus and asset-light oilfield model.
• Clariant: Undergoing restructuring, but generally targets higher margin profiles (17-18% EBITDA margins vs. Stepan’s 8-9%).¹⁴

Stepan is currently performing at the bottom of its peer group in terms of capital efficiency, resembling a commodity bulk chemical producer rather than a specialty ingredients provider.

3.2 Margin Analysis: Structural vs. Cyclical

• Gross Margin: Margins have compressed from a historical band of 15-18% down to 11.9% (TTM Q3 2025).⁸ This compression persists despite volume recovery, signaling an inability to fully capture value in an inflationary environment. The reliance on oleochemicals (coconut oil) introduces volatility that the company struggles to hedge effectively.
• Operating Margin: TTM Operating Margin is a meager 3.3%.⁸ For a “specialty” chemical company, this is dangerously low. It leaves almost no room for error against operational mishaps. We have seen this vulnerability play out: the Millsdale plant outage in 2020 and the Asia fraud event in 2024 both had outsized impacts on the bottom line because the underlying margin buffer was so thin.
• EBITDA Margin: Adjusted EBITDA margins have hovered in the high single digits (~8-9%).¹⁵ Management targets are likely double digits, but actual performance has lagged for eight consecutive quarters.

3.3 Unit Economics and Volume Trends

Recent quarters (2024-2025) tell a story of volume fighting price.

• 2024: Volumes declined/flatlined due to massive industry destocking.¹⁶
• 2025: Volumes returned to modest growth (+4% in Q1, +1% in Q2/Q3).⁷
• The Disconnect: Despite volume growth, operational leverage has not materialized on the bottom line to the extent expected. Higher sales volumes in Surfactants (+3% Q1 2025) were driven by lower-margin agricultural/oilfield recovery, while high-margin Consumer Products volumes softened (-2% in Q3 2025).³ This negative mix shift acts as a headwind to margin expansion even as top-line grows. The company is selling more pounds of lower-margin product, a classic symptom of commoditization.

3.4 Through-Cycle Performance

Stepan prides itself on recession resistance (cleaning products are staples). However, the 2022-2025 period has proven that the company is highly sensitive to inflationary cycles. While volume may be sticky during a demand recession, margins are fragile during a supply shock. The inability to pass through costs instantaneously resulted in a severe earnings trough. Net Income fell from ~$147 million in 2022 to ~$50 million in 2024.⁴ This 66% decline in earnings during a period of economic expansion (albeit inflationary) destroys the “defensive” thesis often attached to the stock.

4. Growth Analysis: A Capital-Intensive Pivot

Stepan’s growth strategy has shifted from steady organic expansion to a more aggressive, capital-heavy repositioning. The success of this pivot is the single most important variable for the stock’s future.

4.1 The Pasadena Gambit

The core of the growth thesis is the new Pasadena, Texas alkoxylation facility.

• The Thesis: Moving capacity to the US Gulf Coast (USGC) provides access to cheaper ethylene/propylene oxide feedstocks via pipeline (avoiding rail logistics costs) and proximity to key agricultural and oilfield customers. It replaces capacity constrained at the aging Millsdale, Illinois plant, theoretically improving reliability and cost structure.
• The Reality: The project has been a drag on earnings for two years.

• Cost: Budgeted at ~$220 million ¹⁸, actual costs likely exceeded this due to the inflationary construction environment of 2022-2024.
• Earnings Drag: The facility incurred $8.6 million in start-up costs in Q3 2025 alone.¹⁹ Depreciation expense is ramping up before revenue fully materializes, creating a mismatch that punishes EPS.
• Outlook: Management promises full financial contribution in 2026.¹⁹ This facility must operate at high utilization to cover its massive fixed cost base. If demand in the agricultural or oilfield sectors falters in 2026, this asset could become a massive drag on ROIC, effectively a “stranded asset” in terms of economic return.

4.2 End-Market Dynamics and Growth Drivers

• Agriculture: Stepan provides emulsifiers and adjuvants for crop protection. This market is recovering from severe destocking in 2023-2024. Double-digit growth reported in 2025 suggests a cyclical upswing, but this is a volatile, weather-dependent market. It is not a secular growth engine in the same way as life sciences or tech.
• Oilfield: Surfactants for Enhanced Oil Recovery (EOR) and friction reducers. This segment has shown high growth recently (+mid-single digits), tied to oil prices hovering around $70-80/bbl.³ However, this demand is precarious. A collapse in oil prices below $60/bbl would likely cause EOR budgets to be slashed, evaporating this demand quickly. Investing in Stepan as a proxy for oilfield activity is an inefficient way to play energy markets.
• Consumer Products (Laundry/Personal Care): The historical “cash cow” is largely stagnant or declining in volume (-2% surfactant volume in Q3 2025 driven by consumer softness).³ This suggests Stepan is losing share to competitors or the market is contracting as consumers trade down to cheaper, less surfactant-intensive private label products. If the core business is shrinking while the “growth” business (Ag/Oil) is volatile, the terminal value of the company is lower than the market appreciates.

4.3 M&A Track Record

Stepan’s acquisition history is mixed and reflects a strategy of consolidation rather than transformation.

• INVISTA (2021): Acquired the aromatic polyester polyol business. Strategically sound for the Polymers business as it consolidated market share. Integration appears successful, helping drive Polymer volumes when the market allows. However, buying commodity capacity does not improve the “quality” of the earnings stream.
• PerformanX (2022): A smaller acquisition to bolster niche surfactant offerings.
• Critique: Management tends to buy assets to gain “capacity” or “market share” in mature industries. There is little evidence of buying high-growth, high-margin IP that transforms the business profile (like Croda’s acquisition of Avanti for lipid nanoparticles). The focus is on scale rather than scope or proprietary technology, which reinforces the commodity nature of the business.

4.4 R&D and Innovation

Stepan spends approximately $57 million annually on R&D, which is roughly 2.5% of sales.²⁰

• Peer Comparison: This is significantly lower than peers like Clariant (~3-4% of sales) ²¹ and Croda (which invests heavily in innovation).
• Innovation Trap: While management touts bio-based surfactants and rPET polyols, the financial statements show a company growing through capital expenditure, not innovation pricing power. True innovation shows up in expanding gross margins; Stepan’s are contracting. This indicates they are spending R&D dollars just to maintain parity in a commoditizing market—the “Red Queen effect” where one must run fast just to stay in the same place.

5. Capital Allocation & Management Quality

Management’s primary job is allocating capital to generate returns. Stepan’s record here is increasingly questionable, characterized by a rigidity that may be harming long-term value creation.

5.1 The “Dividend King” Trap?

Stepan is a Dividend King, having raised its dividend for 58 consecutive years.

• The Cost: The company pays out approx. $1.55-$1.60 per share annually. With TTM EPS around $1.98-$2.00, the payout ratio is uncomfortably high at ~75-80% of reported earnings.¹²
• Analysis: While the dividend is sacrosanct to the Stepan family (who control the company), sustaining it during a period of heavy capex (Pasadena) has strained the balance sheet. Management prioritizes the dividend streak over deleveraging or opportunistic buybacks. In a capital-intensive industry, this rigidity is a weakness. It forces the company to take on debt to fund growth projects because retained earnings are insufficient after the dividend is paid. Effectively, they are borrowing to pay the dividend, a sustainable strategy only if future returns on capital are high—which they currently are not.

5.2 Balance Sheet Management

• Leverage: Net Debt stands at ~$537 million (Q3 2025).¹⁹ Net Debt/EBITDA is approx. 2.9x-3.0x.²² This is high for a cyclical chemical company entering a period of economic uncertainty.
• Shift: Historically, Stepan ran a very conservative balance sheet (<1.5x leverage). The spike to ~3x leverage to fund Pasadena indicates a change in risk appetite.
• Deleveraging: The path to deleveraging relies entirely on EBITDA growth (the denominator) rather than debt paydown (the numerator), as free cash flow is largely consumed by dividends and maintenance capex. If the 2026 EBITDA ramp from Pasadena misses, Stepan enters a danger zone of high leverage and low returns.

5.3 Insider Alignment and Governance

• Ownership: The Stepan family (Quinn Stepan Jr., etc.) holds significant equity (approx. 5-7% insiders). F. Quinn Stepan Jr. beneficially owns ~1.04 million shares (4.6%).²³ This aligns them with shareholders regarding the dividend. However, high family control can also insulate management from activist pressure to improve operational efficiency or pursue strategic alternatives.
• Management Credibility: Management has repeatedly missed guidance or had to walk back expectations (e.g., Q3 2025 earnings miss, Q2 2025 earnings miss).²⁴ Credibility is currently strained. The narrative of “recovery next quarter” has been played on repeat for 18 months.
• Compensation: Executive compensation includes performance shares tied to ROIC targets. For the 2022-2024 period, the ROIC modifier was negative (-30%) because average ROIC was 5.16%, well below the 8.0% threshold.²³ This confirms that management failed to meet its own capital efficiency goals.

6. Recent Developments & Industry Headwinds

6.1 Operational Hiccups: Signs of Strain

Stepan has suffered from a series of “one-off” operational failures that suggest deeper issues with asset reliability and internal controls:

• Asia Fraud (2024): A social engineering scheme cost the company ~$6.8 million.⁴ While financially survivable, it raises red flags about internal governance controls and cyber-risk management.
• Millsdale Outages: Recurring issues at the flagship Millsdale facility have plagued results in prior years (2020, 2024).²⁵ This aging asset requires significant maintenance capex, further draining free cash flow.
• Pasadena Startup: While “operational,” the significant quarterly drag indicates the ramp is costly and perhaps slower than optimal efficiency would dictate.

6.2 The Raw Material Squeeze

• Coconut Oil: Prices averaged $2,500/MT in 2025 vs $1,500/MT in 2024 (+70%).³ Stepan uses significant amounts of lauric oils.
• Lag Effect: While contracts allow pass-through, there is a 30-90 day lag. In a rapidly rising market, margins compress. Management claims they will “recover” this in 2026, but if inflation remains sticky or volatile, the catch-up game never ends. This exposes the weakness of their contracts relative to stronger peers who might have faster pass-through mechanisms.

6.3 Asset Optimization

Recognizing the inefficiency, Stepan is selling non-core assets:

• Philippines Asset Sale: Closed Nov 2025.²⁶
• Lake Providence Sale: Closed Dec 2025.²⁷
• Insight: These divestitures are positive signals that management is finally pruning low-return assets. However, these are likely low-multiple sales that don’t move the needle massively on the balance sheet but do clean up the operational complexity. It is a necessary “shrinking to grow” strategy, but it confirms that previous capital allocation decisions (building/holding these assets) were suboptimal.

7. Valuation Analysis

7.1 Current Metrics

• Price: ~$63.00
• P/E (TTM): ~31.8x.²⁸ This multiple is optically high due to depressed earnings in the denominator. It is not a growth multiple; it is a “trough earnings” multiple.
• Forward P/E (2026 Est): Consensus estimates project EPS recovery to ~$3.55-$4.79 in 2026.²⁹ Assuming the midpoint (~$4.15), the stock trades at ~15x forward earnings.
• EV/EBITDA: ~10.2x.¹²
• Dividend Yield: ~2.5%.
• Price/Book: ~1.14x.³⁰

7.2 Historical Context

Stepan historically traded at 15x-18x earnings when it was growing and generating 12% ROIC. Paying 15x forward earnings today—for a business with 3% ROIC, higher leverage, and significant execution risk—implies that the market is already pricing in a full recovery. There is no “margin of safety.”

7.3 Relative Valuation

• Commodity Chemical Peers (Huntsman, Olin): Trade at 6x-8x EBITDA. Stepan trades at a premium (10x), likely due to the “consumer staple” halo of its surfactant business.
• Specialty Peers (Croda): Trade at 20x+ P/E. Stepan is not Croda. It lacks the IP, margins, and Life Sciences exposure.
• Conclusion: Stepan is priced in “no man’s land”—too expensive for a commodity chemical company, but lacking the quality to justify a specialty multiple.

7.4 Scenario Analysis

• Bull Case (Recovery): Pasadena executes perfectly, adding $30M+ EBITDA. Ag/Oil markets boom. Margins expand to 5%. EPS hits $5.00 in 2027. Applying an 18x multiple yields a price of $90. (Upside: ~40%).
• Bear Case (Stagnation): Margins remain structurally lower due to Tier 2/3 strategy (3.5% operating margin). Pasadena simply replaces lost Millsdale volume without adding net growth. EPS stalls at $2.50. Market re-rates stock to commodity multiple (12x). Price target: $30. (Downside: ~50%).

Assessment: The risk/reward is skewed to the downside. The market is capitalizing normalized earnings that haven’t materialized yet.

8. Risks & Red Flags

1. Commoditization of Core Surfactants: The “Tier 2/3” customer strategy is a tacit admission that Stepan cannot compete on margin with Tier 1s or that Tier 1s are insourcing. Tier 2/3 customers are more credit-risk prone and cost-sensitive.
2. Execution Risk at Pasadena: If the plant does not reach 80%+ utilization by 2026, the ROIC drag will persist, and the debt burden will become heavier.
3. Cyclical Polymer Exposure: A recession in 2026 would crush the rigid polyol business (construction) just as the surfactant business tries to recover.
4. Family Control: Lack of external accountability. Management tenure is long, and fresh perspectives may be lacking.
5. Raw Material Volatility: The business has shown it cannot effectively hedge extreme moves in coconut/palm oil. Climate change affecting crop yields in SE Asia represents a long-term threat to feedstock costs.

9. Conclusion: A Mediocre Business Priced as a Quality Compounder

Does Stepan Company have a genuine competitive advantage?

No. The evidence is clear:

• Financials: ROIC has collapsed to ~3.2%, destroying shareholder value.
• Pricing: Gross margins have compressed despite “pass-through” mechanisms, indicating a lack of true pricing power.
• Strategy: The pivot to “Tier 2/3” customers and capital-intensive projects (Pasadena) suggests the company is running out of high-quality organic growth avenues in its core markets.
• Differentiation: The “specialty” designation is largely a marketing term for what is effectively a small-batch commodity processing business.

Is it worth investing in?

Avoid / Underweight. At ~$63/share, the stock is not a bargain. You are paying a full multiple for a recovery that is fraught with execution risk. The “Dividend King” status provides a psychological floor, but the payout ratio is stretched.

There are far better opportunities in the chemical sector—either deep value commodity players trading at 6x EBITDA with massive free cash flow yields (e.g., Olin) or true specialty compounders with high ROIC and pricing power (e.g., Croda, Sika). Stepan sits in the “muddy middle”—neither cheap enough to be a value play nor good enough to be a quality compounder.

Final Verdict: Stepan Company is a bad business masquerading as a Dividend King. The dividend is safe for now, but the underlying engine of value creation—return on invested capital—is broken. Until management demonstrates 2-3 quarters of sequential margin expansion and ROIC improvement, capital should be deployed elsewhere.

Frequently Asked Questions

General Questions

• What thoughtful questions have other investors asked about this company? Investors are currently focused on three critical areas:
  1. Margin Recovery: When will the company recover the lag in raw material costs (specifically coconut/palm oil) to return to its historical gross margin range of 17-18%, given they are currently near ~12%?.
  2. Pasadena Execution: Will the new $245M+ alkoxylation facility in Pasadena, Texas, actually deliver the promised volume growth and supply chain efficiencies in 2026 to justify the capital outlay, or will it be a drag on ROIC?.
  3. Customer Strategy: Is the pivot to “Tier 2 and Tier 3” customers (adding 400+ new accounts/quarter) structurally dilutive to operating margins due to higher service costs, even if it diversifies revenue?.

Cyclicality & Earnings Nature

• Are earnings at a cyclical high or cyclical low? Earnings are at a cyclical low. Net income for the trailing twelve months (TTM) is approximately $45-50 million, significantly below the peak of ~$147 million seen in 2022.
• Are earnings driven primarily by the external environment or internal company actions? Currently, they are driven by the external environment (volatile raw material costs like coconut oil rising 70%) and internal investment cycles (start-up costs for the Pasadena plant dragged earnings by $8.6 million in Q3 2025 alone).
• How stable are revenues? Revenues are moderately stable due to volume stickiness in consumer staples (laundry/cleaning), but the profitability on that revenue is highly unstable due to the lag in passing through raw material costs. TTM Revenue is ~$2.3 billion, down slightly from peaks but relatively consistent.
• Outlook for the company’s products and services? The outlook is mixed. The core Surfactants business (cleaning) is seeing volume declines (-2% in Q3 2025) due to consumer softness, while the “growth” engines in Agriculture and Oilfield chemicals are seeing double-digit volume growth.
• How big will this market be? Is it growing? Shrinking? Domestic or international? The global surfactants market is estimated at ~$47-48 billion and is projected to grow at a CAGR of roughly 5.4% through 2033. It is a growing, international market, with Asia-Pacific holding the largest share, though Stepan is heavily weighted toward North America.

Business Quality & Competitive Moat

• Is the industry getting more or less competitive? More competitive. The industry is fragmented with intense price competition from global giants (BASF, Evonik, Dow) and internal production by major customers (P&G, Unilever).
• How profitable is this business? What is the return on capital invested? Return on equity? Profitability is currently poor.
  • ROIC: ~3.2%, which is well below the cost of capital (WACC ~8.9%), indicating value destruction.
  • ROE: ~3.7%.
  • Net Margin: ~2.0% (historically 4-5%).
• How profitable is this industry? Are there a lot of competitors? What are the barriers to entry? The specialty chemicals industry typically targets EBITDA margins of 15-20%, but Stepan lags at ~8.6%. There are many competitors, ranging from huge conglomerates to small regional players. Barriers to entry are moderate (capital intensive plants, regulatory compliance), but barriers to profitability are high due to supplier power and customer concentration.
• Can this business be easily understood? Yes. It is a processor business: it buys raw materials (fats/oils), processes them (sulfonation/alkoxylation), and sells ingredients to manufacturers of soaps, insulation, and drugs.
• Can this company be undermined by foreign, low-cost labor? Not significantly for its core US/EU markets, as shipping liquid chemicals long distances is expensive (logistics barrier). However, in Asian markets, it faces fierce competition from local low-cost producers.
• Do brands matter? No. Stepan sells intermediate ingredients. Its “brand” is reliability and supply chain security, not a consumer brand.  
• What is the nature of competition? Price and reliability. Customers will switch for a fraction of a cent per pound if specifications are met, unless the product is a specialized formulation (Agricultural/Pharma).
• What are the customers switching costs? Low for commodity surfactants (laundry/soap). Medium-to-High for agricultural and functional fluids where the chemical is part of a registered EPA formulation.
• What are the barriers to entry? Capital requirements (building a plant costs $100M+) and environmental regulations (handling hazardous materials like ethylene oxide).

Financial Condition & Balance Sheet

• Does the company have assets that are not fully recognized in the balance sheet? Likely its real estate (land owned for decades at historical cost) and some intellectual property (patents/formulations), though the value of these is tied to the low-margin operations they support.
• What off-balance sheet liabilities does the company have? The company has environmental remediation obligations ($19.4 million accrued recently) and potentially underfunded pension obligations, though recent buyouts have reduced this risk.
• How conservative is the company’s accounting? Generally conservative, but the “Adjusted Net Income” metrics heavily exclude “deferred compensation” and “environmental reserves,” which are real costs of doing business, painting a rosier picture than GAAP reality.
• How CapEx hungry is this business? Very hungry. The company spent over $245 million just on the Pasadena facility. Maintenance CapEx is also significant to keep aging chemical plants safe and compliant.

Capital Allocation & Management

• How much free cash flow does the business generate? How does management use this free cash flow? What is their philosophy? Free Cash Flow (FCF) has been volatile and often negative during the recent CapEx cycle (negative $25.8M in Q1 2025, positive $40.2M in Q3 2025). Management prioritizes the Dividend (Dividend King status) above all else, followed by CapEx for growth, and then debt repayment.
• Has the company made any significant acquisitions recently? Yes, the acquisition of the INVISTA polyester polyol business (2021) and PerformanX (2022) to bolster the Polymers and Surfactants segments.
• Is the company buying back shares? Minimal to none. The priority is the dividend and deleveraging from the Pasadena investment.
• Does the company issue large amounts of new shares to insiders? No, share count has remained relatively stable (approx. 22.6 million shares).
• What is the compensation policy of directors and management? Compensation includes base salary and incentives tied to Corporate Net Income and an ROIC modifier. However, ROIC targets were missed recently (-30% modifier triggered for 2022-2024 cycle), indicating pay-for-performance alignment is present but performance is lacking.
• What are the motivations of management? The Stepan family (F. Quinn Stepan Jr.) still holds significant ownership (~4.6%), so they are motivated to maintain the dividend and long-term survival of the family legacy.

Valuation & Market Data

• Is the stock an ADR? MLP? K-1? No. It is a standard C-Corporation (NYSE: SCL).
• Dividend Policy? “Dividend King” with 58 consecutive years of increases. Current yield is ~2.5%. Payout ratio is high at ~77-78% of earnings.
• How profitable is this business? Currently low profitability (2% net margin).
• Is net income diverging from cash from operations? Yes. In Q3 2025, Net Income was ~$10.8 million while Cash from Operations was ~$69.8 million. This divergence is partly due to high non-cash depreciation from the new plant and working capital timing.

Risks & Downside

• What factors would cause the stock to decline?
  1. Pasadena Failure: If the new plant cannot reach high utilization rates in 2026, fixed costs will crush margins further.
  2. Dividend Cut: If earnings don’t recover, the payout ratio (>75%) becomes unsustainable, risking the “Dividend King” premium.
  3. Recession: A downturn in construction would hit the Polymers segment (insulation) hard.
• What is the risk of a catastrophic loss? Low probability of bankruptcy due to stable demand for cleaning products and decent liquidity ($118M cash + credit lines), but high risk of “dead money” (stock stagnating).
• Chance of a total loss? Extremely low. The assets (plants, land, inventory) and staple nature of the products provide a floor.

Recent News & Events

• Has the business environment changed recently? Yes, raw material costs (coconut oil) spiked 70% in 2025, compressing margins.
• Has the company made any significant acquisitions recently? No major acquisitions in 2024-2025; they are currently divesting non-core assets (e.g., closing the sale of Philippines assets in late 2025).
• Has the company recently changed accounting policies? No major changes, though they are adapting to new segment reporting standards and global minimum tax rules.
• Recent changes in the business, new markets, new production facilities, what’s changed recently? New management?
  • Facility: The Pasadena, Texas alkoxylation plant became operational in 2025.
  • Management: Luis Rojo became CEO in October 2024, replacing Scott Behrens.
  • Strategy: Aggressive push to acquire smaller “Tier 2/3” customers to reduce reliance on Tier 1 giants.

Works cited

1. Surfactants Market Size, Share, Trends, Industry Analysis Report, accessed February 10, 2026, https://www.polarismarketresearch.com/industry-analysis/surfactants-market
2. Surfactants Market Size to Hit USD 76.81 Billion by 2034, accessed February 10, 2026, https://www.precedenceresearch.com/surfactants-market
3. Stepan (SCL) Q3 2025 Earnings Call Transcript – The Motley Fool, accessed February 10, 2026, https://www.fool.com/earnings/call-transcripts/2025/10/30/stepan-scl-q3-2025-earnings-call-transcript/
4. 10-K – SEC.gov, accessed February 10, 2026, https://www.sec.gov/Archives/edgar/data/94049/000095017025029079/scl-20241231.htm
5. Stepan Company (SCL) Q2 2025 Earnings Call Transcript, accessed February 10, 2026, https://seekingalpha.com/article/4806266-stepan-company-scl-q2-2025-earnings-call-transcript
6. Stepan Company Executes Agreement to Acquire U.S. Surfactants, accessed February 10, 2026, https://stepan.gcs-web.com/news-releases/news-release-details/stepan-company-executes-agreement-acquire-us-surfactants
7. Stepan Reports First Quarter 2025 Results – PR Newswire, accessed February 10, 2026, https://www.prnewswire.com/news-releases/stepan-reports-first-quarter-2025-results-302440588.html
8. Breaking Down Stepan Company (SCL): Key Insights for Investors, accessed February 10, 2026, https://www.dcfmodeling.com/blogs/health/scl-financial-health
9. What is Competitive Landscape of Stepan Company?, accessed February 10, 2026, https://portersfiveforce.com/blogs/competitors/stepan
10. Stepan ROI – Return on Investment 2012-2025 | SCL – Macrotrends, accessed February 10, 2026, https://www.macrotrends.net/stocks/charts/SCL/stepan/roi
11. SCL (Stepan Co) ROIC % – GuruFocus, accessed February 10, 2026, https://www.gurufocus.com/term/roic/SCL
12. Stepan Company (SCL) Statistics & Valuation – Stock Analysis, accessed February 10, 2026, https://stockanalysis.com/stocks/scl/statistics/
13. COIHY (Croda International) ROIC % – GuruFocus, accessed February 10, 2026, https://www.gurufocus.com/term/roic/COIHY
14. Results, Reports and Publications – Clariant, accessed February 10, 2026, https://www.clariant.com/en/Investors/Results-Reports-and-Publications
15. Stepan EBITDA Margin 2012-2025 | SCL – Macrotrends, accessed February 10, 2026, https://www.macrotrends.net/stocks/charts/SCL/stepan/ebitda-margin
16. Stepan Reports Third Quarter 2025 Results, accessed February 10, 2026, https://stepan.gcs-web.com/news-releases/news-release-details/stepan-reports-third-quarter-2025-results
17. Stepan Reports Third Quarter 2025 Results – PR Newswire, accessed February 10, 2026, https://www.prnewswire.com/news-releases/stepan-reports-third-quarter-2025-results-302597881.html
18. Stepan to Expand Alkoxylation Capacity with U.S. Gulf Coast, accessed February 10, 2026, https://stepan.gcs-web.com/news-releases/news-release-details/stepan-expand-alkoxylation-capacity-us-gulf-coast-investment
19. Stepan Company (SCL) investor relations material – Quartr, accessed February 10, 2026, https://quartr.com/companies/stepan-company_4540
20. Stepan Research and Development Expenses 2012-2025 | SCL, accessed February 10, 2026, https://www.macrotrends.net/stocks/charts/SCL/stepan/research-development-expenses
21. Integrated Report 2024 – Clariant, accessed February 10, 2026, https://www.clariant.com/en/Company/Integrated-Report/Integrated-Report-2024
22. Stepan Q2 2025 slides reveal 27% adjusted earnings growth, accessed February 10, 2026, https://www.investing.com/news/company-news/stepan-q2-2025-slides-reveal-27-adjusted-earnings-growth-polymers-segment-shines-93CH-4160151
23. DEF 14A – SEC.gov, accessed February 10, 2026, https://www.sec.gov/Archives/edgar/data/94049/000119312525061867/d924332ddef14a.htm
24. Stepan Company (SCL) Earnings Report – StockInvest.us, accessed February 10, 2026, https://stockinvest.us/earnings-report/SCL
25. Earnings call: Stepan Company reports mixed results with strategic, accessed February 10, 2026, https://www.investing.com/news/stock-market-news/earnings-call-stepan-company-reports-mixed-results-with-strategic-focus-93CH-3309074
26. Stepan Company Completes Sale of Philippine Assets, Advancing, accessed February 10, 2026, https://stepan.gcs-web.com/news-releases/news-release-details/stepan-company-completes-sale-philippine-assets-advancing
27. Stepan Company closes sale of Lake Providence plant assets, accessed February 10, 2026, https://www.stocktitan.net/news/SCL/stepan-company-announces-closing-of-sale-of-lake-providence-la-e6lqzqab26so.html
28. SCL – Stepan PE ratio, current and historical analysis – FullRatio, accessed February 10, 2026, https://fullratio.com/stocks/nyse-scl/pe-ratio
29. Stepan Company (SCL) Stock Forecast & Analyst Price Targets, accessed February 10, 2026, https://stockanalysis.com/stocks/scl/forecast/
30. Stepan Price/Book Ratio 2012-2025 | SCL – Macrotrends, accessed February 10, 2026, https://www.macrotrends.net/stocks/charts/SCL/stepan/price-book